Ori Biotech
We're on a mission to enable widespread patient access to a new generation of lifesaving Cell and Gene Therapies.
We're on a mission to enable widespread patient access to a new generation of lifesaving Cell and Gene Therapies.
Ori Biotech is a London- and Philadelphia-based startup focused on CGT manufacturing technology with a mission to enable widespread patient access to a new generation of lifesaving Cell and Gene Therapies. Founded in 2015, Ori has developed a proprietary, bespoke, and flexible manufacturing platform that fully automates and standardizes CGT manufacturing in a closed platform, allowing seamless scalability from pre-clinical process development to commercial scale manufacturing. The company's Series B investment of $100.00M in January 18, 2022, backed by a consortium of investors including Octopus Ventures, Amadeus Capital Partners, Chimera Investments, Delin Ventures, Northpond Ventures, Novalis LifeSciences, and Puhua Capital, reflects its potential to address complex manufacturing challenges in the CGT space. Ori Biotech operates at the intersection of Automation, Biotechnology, Health and Wellness, and Manufacturing, positioning itself as a key player in the future of personalized medicine.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $100.00M | 7 |
|
18 Jan 2022 |
| Series A | $30.00M | 3 |
|
14 Oct 2020 |
| Seed Round | £7.00M | - | 09 Jan 2020 |
No recent news or press coverage available for Ori Biotech.
We care about your data, and we'd love to use cookies make your experience better.
